8/29/2012 9:50:44 AM
SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced that Pfizer has selected a third target under its multi-year research and development collaboration with Theraclone. The collaboration, which began in January 2011, uses Theraclone’s I-STAR™ technology to discover monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer. I-STAR™ technology is used to screen and identify novel human antibodies to pathogenic agents and endogenous therapeutic targets.
comments powered by